Novel selective CYP11B1 Inhibitors
Scientists of Saarland University have recently succeeded in developing the first CYP11B1 inhibitors showing good selectivity. As starting point the highly active CYP11B1 inhibitor Etomidate has been used. Via several modifications followed by further optimizations realized at this molecule, it was possible to increase the selectivity resulting in a very weak inhibition towards CYP11B2 and no inhibition of CYP17 and CYP19.
Further Information: PDF
Universität des Saarlandes Wissens- und Technologietransfer GmbH PatentVerwertungsAgentur der saarländischen Hochschulen
Phone: +49 (0)681/302-71302
Contact
Dipl.-Kfm. Axel Koch (MBA), Dr. Conny Clausen, Dr. Hauke Studier, Dr. Susanne Heiligenstein
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Economies take off with new airports
A global study by an SUTD researcher in collaboration with scientists from Japan explores the economic benefits of airport investment in emerging economies using nighttime satellite imagery. Be it for…
CAR T–cell immunotherapy targets
Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targets. Scientists at St. Jude Children’s Research Hospital found 156 potential CAR targets across the brain and solid tumors,…
Stony coral tissue loss disease
… is shifting the ecological balance of Caribbean reefs. The outbreak of a deadly disease called stony coral tissue loss disease is destroying susceptible species of coral in the Caribbean…
